• News


Home>NEWS & MEDIA>News

Daewoong Pharmaceutical Obtains “Composition Patent on EGF” in Japan
Day : 2006-03-06

Daewoong Pharmaceutical Obtains “Composition Patent on EGF” in Japan

Daewoong Pharmaceutical obtained a composition patent on EGF (Epidermal Growth Factor), wound healing factor, in Japan on January 20th 2006.

The patent will increase the stabilization of EGF by mixing the existing EGF with carbomer, a stabilizer. With this mixture, human EGF can fully show its ability to heal wounds.

Daewoong Pharmaceutical is planning to introduce a new concept to the wound healing market by developing new creams and gels with this patent. For this purpose, it is now independently putting a wound healing TFT into full operation to focus on research and development.

Daewoong Pharmaceutical is steadily reaching its dream of being listed as one of the world’s top 50 pharmaceutical companies in the wound healing market. In 1995, it succeeded in mass production of EGF containing high activity and purity. Using this EGF, Easyef solutions were developed and have achieved recognition for its efficacy.

Prev Daewoong Pharmaceutical, KITECH Sign MOU for Biopharma cGMP Facilities
Next The Excellence of EGF Reported In an International SCI Journal